Referencia número: HY-B0631

Alendronic acid

10 Cited Publications

Revisión del cliente

Based on 10 publication(s) in Google Scholar

Alendronate acid is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate acid induces skeletal alterations in the chicken embryonic development model. Alendronate acid can be used for osteoporosis research.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 98.0%
No. CAS: 66376-36-1
Fòrmula: C₄H₁₃NO₇P₂
Peso molecular:249.10

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Alendronic acid Chemical Structure

No. CAS: 66376-36-1

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vivo
Chemical Information
Publications (10)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[3]

IL-6

NF-κB

Ver todos los productos específicos de isoformas NF-κB :

Ver todos los productos específicos de isoformas Interleukin Related :

Cellular Effect

Cell Line	Type	Value	Description	References
BMDM	IC₅₀	4.22 μM Compound: ALN	Inhibition of osteoclastogenesis in C57BL/6J mouse Bone marrow macrophage cells assessed as inhibition of RANKL-stimulated osteoclast formation measured after 6 days by tartrate-resistant acid phosphatase (TRAP) staining assay Inhibition of osteoclastogenesis in C57BL/6J mouse Bone marrow macrophage cells assessed as inhibition of RANKL-stimulated osteoclast formation measured after 6 days by tartrate-resistant acid phosphatase (TRAP) staining assay	[PMID: 39185622]
HFF	IC₅₀	108.8 μM Compound: 45	In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells) In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)	[PMID: 15857119]
MCF7	IC₅₀	69.5 μM Compound: Alendronate	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay	[PMID: 33132173]
T-cell	EC₅₀	0.9 μM Compound: Alendronate	Effective concentration to activate gammadelta T cells Effective concentration to activate gammadelta T cells	[PMID: 12383012]
T-cell	EC₅₀	32 μM Compound: 2	Effective concentration against human Gamma delta T cells Effective concentration against human Gamma delta T cells	[PMID: 15828834]
T-cell	IC₅₀	52 μM Compound: 32	Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL	[PMID: 14711309]
T-cell	IC₅₀	53 μM Compound: 32	Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release	[PMID: 14711309]
Vero	IC₅₀	25 μM Compound: 1	Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum	[PMID: 11300872]

In Vivo

Alendronate (1.5E⁻¹⁰-1.5E⁻⁷ M, intra-air cell injection, single dose at embryonic day 7, exposure for 4 days) acid induces skeletal alterations in the chicken embryonic development model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Viable fertilized chick eggs (7 days)^[3]
Dosage:

1.5E^-7 M, 1.5E^-8 M, 1.5E^-9 M, and 1.5E^-10 M
Administration:

intra-air cell injection, single dose at embryonic day 7, exposure for 4 days
Result:

Showed an 87.5% viability rate and a 75% viability rate at 1.5E^-10 M and other doses, respectively.
Significantly reduced bone morphometric indexes (bone volume (BV) and bone surface (BS)) and cortical thickness in a dose-dependent manner.
Significantly reduced dimensions and diminished mineralization in a concentration-dependent manner.
Significantly increased TNFRSF11B, NF-κB1 and IL-6 levels, and decreased TNFRSF11A, CTSK, COL1A2, SPP1, and SOST levels, compared to control.

Chemical Information

No. CAS 66376-36-1
Appearance Solid
Peso molecular 249.10
Fòrmula C₄H₁₃NO₇P₂
Color White to off-white
SMILES

OC(P(O)(O)=O)(CCCN)P(O)(O)=O
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (10)

All Bio/Physico-chemical AssayCell Imaging/StainingFlow Cytometry

Sort by:

Journal Impact Factor

J Pharm Anal

2025 Jul 31.
Int J Mol Med

Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection. [Abstract]

2025 Dec;56(6):206. PMID: 40999989
Cell Rep

Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. [Abstract]

2022 Oct 25;41(4):111508. PMID: 36288714
J Med Chem

Discovery of Novel Neo-Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ. [Abstract]

2024 Sep 12;67(17):15738-15755. PMID: 39185622

Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]

Alendronate sodium hydrate (33 μM; 48 h) significantly restored mpx expression in Tg(drl:hoxa9) embryos.

Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]

Alendronate sodium hydrate (33 μM; 48 h) recovered macrophage differentiation in Tg(drl:hoxa9) embryos.

Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]

Flow cytometry analysis of CD14 and CD11b expression in U937 cells treated with different doses of Alendronate sodium hydrate (20-40 μM).

Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]

Flow cytometry analysis of CD14 and CD11b expression in U937 cells treated with Alendronate sodium hydrate (30 μM; 3 d).

Alendronic acid purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]

Alendronate sodium hydrate (30 μM) induced chromatin condensation and increased the nucleocytoplasmic ratio in U937 cells, supporting the differentiation of these cells.
Biochem Pharmacol

Irisolidone enhances osteoblast differentiation via the AMPK-ULK1-autophagy Axis to accelerate osteoporotic fracture repair. [Abstract]

2025 Aug 13;242(Pt 1):117234. PMID: 40816626
Int J Mol Sci

In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells. [Abstract]

2024 Jul 16;25(14):7798. PMID: 39063039
Am J Physiol Endocrinol Metab

Mononuclear phagocyte morphologic response to chemoattractants is dependent on geranylgeranyl pyrophosphate. [Abstract]

2024 Jul 1;327(1):E55-E68. PMID: 38717364
J Biol Chem

Mature osteoclast-derived apoptotic bodies promote osteogenic differentiation via RANKL-mediated reverse signaling. [Abstract]

2019 Jul 19;294(29):11240-11247. PMID: 31167789
Bone

Inhibiting autophagy further promotes Ginkgolide B's anti-osteoclastogenesis ability. [Abstract]

2025 Mar:192:117348. PMID: 39617111
Pathol Res Pract

Alendronate-functionalized ZIF-8 nanoplatform for targeted delivery of SHH siRNA and docetaxel to treat prostate cancer bone metastasis. [Abstract]

2025 Sep:273:156138. PMID: 40694986

Solvente y solubilidad

In Vitro:

H₂O : 3.7 mg/mL (14.85 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0145 mL

20.0723 mL

40.1445 mL

5 mM

0.8029 mL

4.0145 mL

8.0289 mL

10 mM

0.4014 mL

2.0072 mL

4.0145 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 6.67 mg/mL (26.78 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (276 KB)
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Imai K. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging. 2013;8:681-688. [Content Brief]

[2]. Sharpe M, et al. Alendronate: an update of its use in osteoporosis. Drugs. 2001;61(7):999-1039. [Content Brief]

[3]. de Campos WG, et al. Alendronate induces skeletal alterations in the chicken embryonic development model. Toxicol Appl Pharmacol. 2023 Oct 1;476:116673. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	4.0145 mL	20.0723 mL	40.1445 mL	100.3613 mL
	5 mM	0.8029 mL	4.0145 mL	8.0289 mL	20.0723 mL
	10 mM	0.4014 mL	2.0072 mL	4.0145 mL	10.0361 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Alendronic acid

10 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Alendronic acid

Bioactive Compound Library Max

Bioactive Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Alendronic acid

Ver todos los productos específicos de isoformas NF-κB

Ver todos los productos específicos de isoformas Interleukin Related

Actividad biológica

Chemical Information

Publications (10)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Alendronic acid Related Classifications

HY-B0631 Related Classifications